Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
Modeyso Included in National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
LAURION Reports Multiple High-Grade Intercepts, Including 15.35 g/t Au over 0.50 m , 7.30 g/t Au over 0.50 m , and a Broad 3.0 m Interval of 1.09 g/t Au
Kingsmen Drills a New Discovery of High Grade Silver and Gold Mineralization (931 g/t Silver Equivalent with 1.28 g/t Gold over 1.60 Meters (156.4-158.0m))
Nine Mile Metals Announces Completion of DDH WD-25-02 and Continues to Confirm (2) Zones of Copper Rich VMS Mineralization at the Wedge Project Drill Program
SAGA Metals Completes Phase 1 & Commences Phase 2 of Drilling at Radar Project in Labrador-Confirms Extensive Oxide Mineralization Over 1.5 Km & Provides Corporate Update
Cassiar Gold Drills 13.53 g/t Gold over 13.4 Meters from 28.2 Meters Downhole, Including 210.71 g/t Gold over 0.8 m with 369.00 g/t Gold over 0.4 Meters from 39.8 m Downhole, Extends Higher-Grade Domains at the Taurus Deposit
